Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
20 Junio 2024 - 7:00AM
Oragenics, Inc. (NYSE American: OGEN), a company focused on
developing unique, intranasal pharmaceuticals for the treatment of
neurological disorders, today announced that it received a notice
(the “Notice”) from the NYSE American LLC (the “NYSE American”)
dated June 18, 2024, notifying the Company that it has accepted the
Company’s plan to regain compliance with NYSE American’s continued
listing standards.
The NYSE American has reviewed Oragenics’ compliance plan and
information submitted on May 17, 2024, and determined that the
Company made a reasonable demonstration of its ability to make
substantial progress toward regaining compliance by October 18,
2025. During this time, the Company will be subject to quarterly
monitoring for compliance with the plan. If the Company does not
regain compliance with NYSE American’s listing standards by October
18, 2025, or if the Company does not make sufficient progress
consistent with its plan, then the NYSE American may initiate
delisting proceedings at that time.
About Oragenics
Oragenics is a development-stage biotechnology company focused
on nasal delivery of pharmaceutical medications in neurology and
fighting infectious diseases, including drug candidates for
treating mild traumatic brain injury (mTBI), also known as
concussion, and for treating Niemann Pick Disease Type C (NPC), as
well as proprietary powder formulation and an intranasal delivery
device. For more information, please
visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including
with regard to the Company’s ability to regain compliance with the
NYSE American’s continued listing standards by October 18, 2025.
These forward-looking statements are based on management’s beliefs
and assumptions and information currently available. The words
"believe," "expect," "anticipate," "intend," "estimate," "project"
and similar expressions that do not relate solely to historical
matters identify forward-looking statements. Investors should be
cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors
that could cause actual results to differ materially from those
expressed in any such forward-looking statements. These factors
include, but are not limited to those described in our Form 10-K
and other filings with the U.S. Securities and Exchange Commission.
All information set forth in this press release is as of the date
hereof. You should consider these factors in evaluating the
forward-looking statements included in this press release and not
place undue reliance on such statements. We do not assume any
obligation to publicly provide revisions or updates to any
forward-looking statements, whether as a result of new information,
future developments or otherwise, should circumstances change,
except as otherwise required by law.
Oragenics, Inc.Janet Huffman, Chief Financial
Officer813-286-7900jhuffman@oragenics.com
Oragenics (AMEX:OGEN)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Oragenics (AMEX:OGEN)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024